Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery.

[1]  R. Califf,et al.  Anti-Platelet Factor 4/Heparin Antibodies: An Independent Predictor of 30-Day Myocardial Infarction After Acute Coronary Ischemic Syndromes , 2003, Circulation.

[2]  D. Mangano.  Aspirin and mortality from coronary bypass surgery. , 2002, The New England journal of medicine.

[3]  W. White,et al.  The Association of Complication Type with Mortality and Prolonged Stay After Cardiac Surgery with Cardiopulmonary Bypass , 2002, Anesthesia and analgesia.

[4]  H. Ackermann,et al.  Determination of heparin–platelet factor 4–IgG antibodies improves diagnosis of heparin‐induced thrombocytopenia , 2001, British journal of haematology.

[5]  J. Kelton,et al.  Temporal aspects of heparin-induced thrombocytopenia. , 2001, The New England journal of medicine.

[6]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[7]  B. Chong,et al.  Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. , 2000, Blood.

[8]  Y. Gruel,et al.  Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. , 1999, Circulation.

[9]  M. Trossaërt,et al.  High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery , 1998, British journal of haematology.

[10]  C. Greenberg,et al.  Heparin-associated Thrombocytopenia and Thrombosis: Implications for Perioperative Management , 1997, Anesthesiology.

[11]  W. Hauck,et al.  Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. , 1997, Circulation.

[12]  W. White,et al.  Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. , 1997, JAMA.

[13]  R. Aster,et al.  Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. , 1996, The Journal of laboratory and clinical medicine.

[14]  D. Silver,et al.  Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. , 1992, The Annals of thoracic surgery.

[15]  A. Bernstein,et al.  A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. , 1989, Circulation.

[16]  A. Girolami,et al.  The release of β‐ thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery , 1981 .

[17]  J. Francis,et al.  Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. , 2003, The Annals of thoracic surgery.

[18]  P J Simpson,et al.  Impact of the patient population on the risk for heparin-induced thrombocytopenia. , 2000, Blood.

[19]  A. Girolami,et al.  The release of beta-thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery. , 1981, European journal of clinical investigation.